Innate Pharma (IPHA) announced that its supervisory board has appointed Jonathan Dickinson as the company’s new CEO and chairman of the executive board, effective November 1. Jonathan Dickinson succeeds Herve Brailly, co-founder of the company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as executive VP and general manager, Europe at Incyte (INCY). Herve Brailly, current interim CEO, will stay for the next few months in an advisory role to ensure a smooth transition. It will be proposed that Brailly joins the board at the next opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA: